Skip to main content
. 2020 May 14;69(8):1510–1519. doi: 10.1136/gutjnl-2019-320204

Figure 3.

Figure 3

The gut microbiome is involved in modulating the clinical response to cancer immunotherapy. CTLA-4, cytotoxic T lymphocyte antigen 4; FMT, faecal microbiome transplantation; PD-1, programmed cell death protein 1; PD-L1, programmed cell death protein 1 ligand.